BIIB · Insider Trading
Biogen Inc. Common Stock
Every open-market purchase and sale reported by BIIB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Sean Godbout | Chief Accounting Officer | MIXED | +19 | −$1.76K |
| 2026-09-03 | Michael Parini | Chief Legal Officer | A | +7,405 deriv. | — |
| 2026-08-05 | Lloyd Minor | Director | Sell | −1,186 | −$239.75K |
| 2026-06-11 | Maria C Freire | Director | A | +2,005 | — |
| 2026-06-11 | Eric K Rowinsky | Director | A | +1,505 | — |
| 2026-06-11 | Lloyd Minor | Director | A | +1,505 | — |
| 2026-06-11 | Monish D Patolawala | Director | A | +1,505 | — |
| 2026-06-11 | Jesus B Mantas | Director | A | +1,505 | — |
| 2026-06-11 | William A Hawkins | Director | A | +1,505 | — |
| 2026-06-11 | Stephen A Sherwin | Director | A | +1,505 | — |
| 2026-06-11 | Susan Langer | Director | A | +1,505 | — |
| 2026-06-11 | Menelas N Pangalos | Director | MIXED | +3,875 | — |
| 2026-05-05 | Adam Keeney | Head of Corporate Development | MIXED | +484 | −$85.11K |
| 2026-04-03 | Sean Godbout | Chief Accounting Officer | MIXED | +127 | −$9.92K |
| 2026-02-17 | Susan H Alexander | EVP Chief Legal Officer | A | +8,450 deriv. | — |
| 2026-02-17 | Sean Godbout | Chief Accounting Officer | A | +1,800 deriv. | — |
| 2026-02-17 | Ginger Gregory | EVP, Human Resources | A | +8,025 deriv. | — |
| 2026-02-17 | Jane Grogan | Head of Research | A | +8,450 deriv. | — |
| 2026-02-17 | Rachid Izzar | Head of Global Product Strat. | A | +7,390 deriv. | — |
| 2026-02-17 | Adam Keeney | Head of Corporate Development | A | +8,025 deriv. | — |
| 2026-02-17 | Robin Kramer | Chief Financial Officer | A | +8,450 deriv. | — |
| 2026-02-17 | Nicole Murphy | Head of Pharm Ops and Tech | Buy | +3 | +$585 |
| 2026-02-17 | Priya Singhal | Head of Development | A | +10,560 deriv. | — |
| 2026-02-17 | Christopher Viehbacher | President and CEO | A | +38,015 deriv. | — |
| 2026-02-10 | Susan H Alexander | EVP Chief Legal Officer | MIXED | +5,542 | −$704.93K |
| 2026-02-10 | Sean Godbout | Chief Accounting Officer | MIXED | +720 | −$72.22K |
| 2026-02-10 | Ginger Gregory | EVP, Human Resources | MIXED | +4,594 | −$520.86K |
| 2026-02-10 | Jane Grogan | Head of Research | MIXED | +2,267 | −$199.37K |
| 2026-02-10 | Rachid Izzar | Head of Global Product Strat. | MIXED | +4,851 | −$410.00K |
| 2026-02-10 | Adam Keeney | Head of Corporate Development | MIXED | +3,497 | −$318.47K |
| 2026-02-10 | Robin Kramer | Chief Financial Officer | MIXED | +3,460 | −$310.42K |
| 2026-02-10 | Nicole Murphy | Head of Pharm Ops and Tech | MIXED | +5,386 | −$671.74K |
| 2026-02-10 | Priya Singhal | Head of Development | MIXED | +1,772 | −$1.03M |
| 2026-02-10 | Christopher Viehbacher | President and CEO | MIXED | +13,481 | −$2.21M |
| 2026-02-03 | Priya Singhal | Head of Development | MIXED | +499 | −$238.81K |
| 2025-12-03 | Christopher Viehbacher | President and CEO | MIXED | +3,636 | −$605.16K |
| 2025-11-04 | Jane Grogan | Head of Research | MIXED | +358 | −$51.99K |
| 2025-10-06 | Sean Godbout | Chief Accounting Officer | MIXED | +18 | −$1.24K |
| 2025-09-02 | Priya Singhal | Head of Development | MIXED | +345 | −$175.75K |
| 2025-07-16 | Rachid Izzar | Head of Global Product Strat. | Sell | −2,223 | −$300.11K |
| 2025-06-18 | Caroline Dorsa | Director | A | +3,160 | — |
| 2025-06-18 | Susan Langer | Director | A | +2,370 | — |
| 2025-06-18 | Stephen A Sherwin | Director | A | +2,370 | — |
| 2025-06-18 | Eric K Rowinsky | Director | A | +2,370 | — |
| 2025-06-18 | Maria C Freire | Director | A | +2,370 | — |
| 2025-06-18 | William A Hawkins | Director | A | +2,370 | — |
| 2025-06-18 | Jesus B Mantas | Director | A | +2,370 | — |
| 2025-06-18 | Monish D Patolawala | Director | A | +2,370 | — |
| 2025-06-18 | Lloyd Minor | Director | A | +2,370 | — |
| 2025-06-18 | Menelas N Pangalos | Director | A | +2,370 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Susan H Alexander | EVP Chief Legal Officer | 63,403 | $16.02M |
| Caroline Dorsa | Director | 31,002 | $7.84M |
| Eric K Rowinsky | Director | 25,844 | $6.53M |
| Michael R. McDonnell | EVP, Chief Financial Officer | 25,712 | $6.50M |
| Christopher Viehbacher | President and CEO | 25,451 | $6.43M |
| Ginger Gregory | EVP, Human Resources | 22,358 | $5.65M |
| Nicole Murphy | Head of Pharm Ops and Tech | 19,611 | $4.96M |
| Stephen A Sherwin | Director | 15,193 | $3.84M |
| Jesus B Mantas | Director | 11,263 | $2.85M |
| William A Hawkins | Director | 10,365 | $2.62M |
| Maria C Freire | Director | 8,820 | $2.23M |
| Robin Kramer | Chief Financial Officer | 8,800 | $2.22M |
| Priya Singhal | Head of Development | 8,488 | $2.15M |
| Rachid Izzar | Head of Global Product Strat. | 8,204 | $2.07M |
| Adam Keeney | Head of Corporate Development | 6,820 | $1.72M |
| Susan Langer | Director | 6,634 | $1.68M |
| Monish D Patolawala | Director | 5,215 | $1.32M |
| Jane Grogan | Head of Research | 4,058 | $1.03M |
| Menelas N Pangalos | Director | 3,875 | $979.33K |
| Lloyd Minor | Director | 3,282 | $829.46K |
| Sean Godbout | Chief Accounting Officer | 1,466 | $370.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIIB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.